[1]吴丰月,盖春柳,杨宏伟,等.雷珠单抗玻璃体内注射治疗1型阈值前病变早产儿视网膜病变疗效观察[J].眼科新进展,2020,40(5):478-481.[doi:10.13389/j.cnki.rao.2020.0110]
　WU Fengyue,GAI Chunliu,YANG Hongwei,et al.Efficacy of intravitreal injection of Ranibizumab for treatment of type 1 prethreshold retinopathy of prematurity[J].Recent Advances in Ophthalmology,2020,40(5):478-481.[doi:10.13389/j.cnki.rao.2020.0110]
点击复制

雷珠单抗玻璃体内注射治疗1型阈值前病变早产儿视网膜病变疗效观察/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年5期
页码:
478-481
栏目:
应用研究
出版日期:
2020-05-05

文章信息/Info

Title:
Efficacy of intravitreal injection of Ranibizumab for treatment of type 1 prethreshold retinopathy of prematurity
作者:
吴丰月; 盖春柳; 杨宏伟; 于文婷
110004　辽宁省沈阳市，中国医科大学附属盛京医院眼科（吴丰月，盖春柳，杨宏伟）；110004　辽宁省沈阳市，中国医科大学附属盛京医院新生儿科（于文婷）
Author(s):
WU Fengyue1; GAI Chunliu1; YANG Hongwei1; YU Wenting2
1.Department of Ophthalmology，Shengjing Hospital of China Medical University，Shenyang 110004，Liaoning Province，China
2.Department of Neonatology，Shengjing Hospital of China Medical University，Shenyang 110004，Liaoning Province，China
关键词:
早产儿视网膜病变; 1型阈值前早产儿视网膜病变; 玻璃体内注射; 雷珠单抗
Keywords:
retinopathy of prematurity;  type 1 prethreshold ROP;  intravitreal injection;  Ranibizumab
分类号:
R774
DOI:
10.13389/j.cnki.rao.2020.0110
文献标志码:
A
摘要:
目的　观察雷珠单抗玻璃体内注射治疗1型阈值前病变早产儿视网膜病变（retinopathy of prematurity，ROP）的疗效。方法　回顾性分析2016年4月至2017年8月在我院眼科检查确诊并接受雷珠单抗玻璃体内注射治疗的1型阈值前病变ROP患儿，所有患儿在确诊后72 h内行雷珠单抗0.25 mg/0.025 mL玻璃体内注射，首次注药后2 d、1周、2周以及接下来根据患儿病情决定随访频率并观察治疗效果。结果　12例（20眼）ROP患儿接受雷珠单抗玻璃体内注射治疗，所有眼玻璃体内注射雷珠单抗均有疗效，3例（5眼）出现ROP复发，平均复发时间在治疗后8.8周。1例患儿在双眼注射雷珠单抗后出现单眼复发，所有复发眼接受二次复发时间雷珠单抗玻璃体内注射。末次随访时除1例（2眼）外，其他患眼均达到Ⅲ区血管化。除少量局限的视网膜出血外，未发现与注药治疗相关的局部及全身并发症。结论　雷珠单抗玻璃体内注射治疗1型阈值前病变ROP效果明确，可使视网膜血管继续生长，但存在一定的复发率。
Abstract:
Objective　To observe the efficacy of intravitreal injection of Ranibizumab for treatment of type 1 prethreshold retinopathy of prematurity (ROP).Methods　A retrospective study was performed on type 1 prethreshold ROP patients who received Ranibizumab treatment in Ophthalmology Department of our hospital from April 2016 to August 2017. All of them were treated with intravitreal injection of 0.25 mg/0.025 mL Ranibizumab with in 72 hours after diagnosis. Follow-up examinations were performed at 2 day, 1 week and 2 weeks after treatment and then determined by the patient’s condition. Results　 Twelve ROP patients (20 eyes) received intravitreal injection of Ranibizumab. The treatment was effective for all eyes. However, ROP re-occurred in 3 patients (5 eyes) on average 8.8 weeks after treatment. One patient had unilateral recurrence of ROP after bilateral injection of Ranibizumab. All recurrent eyes required a second intravitreal injection of Ranibizumab. With one (2 eyes) exception, all the other affected eyes exhibited Zone Ⅲ vascularization. There was no local or systemic complications associated with injection treatment except minor localized retinal hemorrhage. Conclusion　Intravitreal injection of Ranibizumab is effective for type 1 prethreshold ROP, and still with growth of retinal blood vessels, but there is a certain recurrence rate.

参考文献/References:

［1］　CHANLING T，GOCK B，STONE J.The effect of oxygen on vasoformative cell division.Evidence that ‘physiological hypoxia’ is the stimulus for normal retinal vasculogenesis［J］.Invest Ophthalmol Vis Sci，1995，36（7）：1201-1214.
［2］　SMITH L E，WESOLOWSKI E，MCLELLAN A，KOSTYK S K，D’AMATO R，SULLIVAN R，et al.Oxygen-induced retinopathy in the mouse［J］.Invest Ophthalmol Vis Sci，1994，35（1）：101-111.
［3］　MINTZ-HITTNER H A，KENNEDY K A，CHUANG A Z；BEAT-ROP Cooperative Group.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity［J］.N Engl J Med，2011，364（7）：603-615.
［4］　MENKE M N，FRAMME C，NELLE M，BERGER M R，STURM V，WOLF S.Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone Ⅱ，stage 3 with plus disease［J］.BMC Ophthalmol，2015，15（1）：20.
［5］　ZHANG G，YANG M，JENG J，VAKROS G，SU K，CHEN M，et al.Comparison of intravitreal injection of ranibizumab versus laser therapy for zoneⅡtreatment-requiring retinopathy of prematurity［J］.Retina，2017，37（4）：710-717.
［6］　FENG J，QIAN J，JIANG Y，ZHAO M，LIANG J，YIN H，et al.Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China［J］.Ophthalmology，2017，124（3）：408-409.
［7］　中华医学会眼科学分会眼底病学组.中国早产儿视网膜病变筛查指南（2014年）［J］.中华眼科杂志，2014，50（12）：933-935.
Ocular Fundus Disease Group of Ophthalmology Branch of Chinese Medical Association.The Chinese screening guide of retinopathy of prematurity（2014）［J］.Chin J Ophthalmol，2014，50（12）：933-935.
［8］　International Committee for the Classification of Retinopathy of Prematurity.The international classification of retinopathy of prematurity revisited［J］.Arch Ophthalmol，2005，123（7）：991-999.
［9］　Early Treatment for Retinopathy of Prematurity Cooperative Group.Revised indications for the treatment of retinopathy of prematurity：results of the early treatment for retinopathy of prematurity randomized trial［J］.Arch Ophthalmol，2003，121（12）：1684-1694.
［10］　Cryotherapy for Retinopathy of Prematurity Cooperative Group.Multicenter trial of cryotherapy for retinopathy of prematurity：preliminary results［J］.Arch Ophthalmol，1988，106（2）：56-57.
［11］　WU W C，SHIH C P，LIEN R，WANG N K，CHEN Y P，CHAO A N，et al.Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity［J］.Retina，2017，37（4）：694-701.
［12］　HOERSTER R，MUETHER P，DAHLKE C，MEHLER K，OBER-THR A，KIRCHHOF B，et al.Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity［J］.Acta Ophthalmol，2013，91（1）：74-75.
［13］　ZHOU Y，JIANG Y，BAI Y，WEN J，CHEN L.Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab［J］.Graefes Arch Clin Exp Ophthalmol，2016，254（1）：31-36.
［14］　DARLOW B A，ELLS A L，GILBERT C E，GOLE G A，QUINN G E.Are we there yet? Bevacizumab therapy for retinopathy of prematurity［J］.Arch Dis Child Fetal Neonatal Ed，2013，98（2）：170-174.
［15］　MORIN J，LUU T M，SUPERSTEIN R，OSPINA L H，LEFEBVRE F，SIMARD M N，et al.Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity［J］.Pediatrics，2016，137（4）：e20153218.

相似文献/References:

[1]杜安杰 任兵 高晓唯 付燕 赵旭东 郭继华.氨基胍对氧诱导的视网膜病变小鼠视网膜神经细胞的保护作用[J].眼科新进展,2012,32(12):000.
[2]王宗华 董文丽 陈思扬.早产儿视网膜病变间接检眼镜激光治疗及危险因素分析[J].眼科新进展,2012,32(12):000.
[3]田妮 郭海科 项道满 陈锋 卢艳华.数字化双目间接检眼镜检查系统在早产儿视网膜病变筛查中的应用[J].眼科新进展,2012,32(12):000.
[4]李蓉 王雨生.早期治疗早产儿视网膜病变的多中心临床试验[J].眼科新进展,2012,32(3):000.
[5]彭娟 沙翔垠 杨瑞明 郑瑜.妊娠并发症及围产期感染与早产儿视网膜病变的关系[J].眼科新进展,2012,32(4):000.
[6]王淋淋 唐兰芬 谭建新 阮豫才 方玉兰.曲尼司特抑制早产儿视网膜病变大鼠模型血管新生和纤维化的实验研究[J].眼科新进展,2013,33(10):000.
[7]韩丽英 李兵.IGF-1对大鼠未成熟视网膜新生血管形成的影响[J].眼科新进展,2013,33(10):000.
[8]张国明 李娜 张福燕. 早产儿视网膜病变和足月新生儿眼病筛查指南[J].眼科新进展,2014,34(2):101.
[9]刘梅.Retcam Ⅲ数字视网膜照相机在早产儿视网膜病变筛查中的应用[J].眼科新进展,2014,34(5):483.[doi:10.13389/j.cnki.rao.2014.0133]
　LIU Mei.Application of Retcam Ⅲ digital camera in retinopathy of premature screening[J].Recent Advances in Ophthalmology,2014,34(5):483.[doi:10.13389/j.cnki.rao.2014.0133]
[10]高尚.视网膜电图在早产儿视网膜病变激光术后视网膜功能评价中的应用[J].眼科新进展,2014,34(6):570.[doi:10.13389/j.cnki.rao.2014.0156]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-05-05